STOCK TITAN

Cocrystal Pharma (COCP) SEC Filings, May-Aug 2026

COCP NASDAQ

Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.

The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.

Rhea-AI Summary

An entity associated with Cocrystal Pharma director and 10% owner Phillip Frost, M.D., Frost Gamma Investments Trust, purchased 75,000 shares of common stock on 2026-08-03 in an open-market or private transaction at a weighted average price of $0.9412 per share, with individual trade prices between $0.87 and $0.9499. Following this purchase, the trust holds 1,983,551 shares of Cocrystal Pharma common stock indirectly. Frost also has 27,100 shares held directly, which include shares issuable upon vesting of restricted stock units. Frost disclaims beneficial ownership of shares held by Frost Gamma Investments Trust and by OPKO Health, Inc., except to the extent of any pecuniary interest, and the transaction is not reported as made under a Rule 10b5-1 trading plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with longtime investor OPKO Health, Inc., under which Cocrystal sold 5,474,053 shares of common stock at $0.9134 per share, the Nasdaq Consolidated Bid Price on the closing date, generating $5.0 million in gross proceeds.

The unregistered private placement to OPKO, an accredited investor, relied on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and included no warrants or other derivative securities. Dr. Phillip Frost, OPKO’s Chairman and CEO, is co-founder, director and principal stockholder of Cocrystal. The company plans to use net proceeds to advance its preclinical and clinical antiviral programs, including lead norovirus candidate CDI-988, and for general corporate purposes and working capital, and expects topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.63%
Tags
current report
-
Rhea-AI Summary

Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. Stockholders voted on electing five directors, ratifying the independent auditor for the fiscal year ending December 31, 2026, and a possible adjournment to solicit additional proxies if needed.

All five director nominees were elected, with votes for each ranging from 5,914,522 to 6,293,331, and 2,860,552 broker non-votes recorded for each nominee. Stockholders ratified Weinberg & Company as the independent registered public accounting firm, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. Because Proposals 1 and 2 received sufficient support, the adjournment proposal was moot.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
current report
Rhea-AI Summary

Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective immediately, under an employment offer letter. He will receive an initial annual base salary of $265,000 and an annual performance bonus targeted at 50% of base salary, tied to Board-set goals.

Sapirstein was granted 10-year stock options to purchase 235,000 shares at an exercise price of $1.05, vesting in four equal annual installments beginning June 3, 2027, with accelerated vesting upon a Change in Control or certain terminations. The Offer Letter also contemplates a potential additional grant of options to purchase another 235,000 shares six months after his start date, subject to performance targets and approvals. He replaces prior Co-CEOs Sam Lee and James Martin, who continue as President/Chief Scientific Officer and Chief Financial Officer, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
current report
-
Rhea-AI Summary

Cocrystal Pharma, Inc. reported that Chief Executive Officer James Sapirstein received a grant of stock options to acquire 235,000 shares of common stock. The options have an exercise price of $1.12 per share and expire on June 3, 2036.

The options were granted under the company’s 2025 Equity Incentive Plan at no cost, vesting in four equal annual installments starting on June 3, 2027, subject to continued employment and potential accelerated vesting upon a Change in Control or termination for Cause as defined in the plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma, Inc. filed an initial ownership report on Form 3 for Chief Executive Officer James Sapirstein. This filing establishes his status as an insider but does not list any buy, sell, or derivative transactions, and shows no current holdings or option positions in the data provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
insider
Rhea-AI Summary

Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. He succeeds former Co-CEOs Sam Lee and Jim Martin; Lee will remain President and become Chief Scientific Officer, while Martin continues as Chief Financial Officer. The company highlights Sapirstein’s extensive antiviral and biopharma leadership experience, including participation in 23 product launches and multiple business development deals. Cocrystal reiterates its focus on structure-based drug discovery to develop next-generation antiviral therapies targeting viruses such as norovirus, influenza, coronaviruses including SARS-CoV-2, and hepatitis C.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
current report
-
Rhea-AI Summary

Cocrystal Pharma is asking stockholders to vote at its 2026 virtual annual meeting on July 14, 2026. Investors will elect five directors for one-year terms, ratify Weinberg & Company as independent auditor for 2026, and approve a potential adjournment to gather additional votes if needed.

The proxy details how to attend and vote electronically, outlines quorum and broker voting rules, and describes board structure and full independence under Nasdaq standards. It highlights key committees, an insider trading and anti-hedging policy, and a clawback policy tied to financial restatements.

Executive pay in 2025 focused on reduced base salaries and equity awards, with Co-CEOs James Martin and Sam Lee earning $265,000 and $248,672 respectively. The filing shows insiders and directors collectively beneficially owning 39.4% of common stock and reports a 2025 net loss of $8.8 million alongside pay-versus-performance disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
proxy
-
Rhea-AI Summary

Cocrystal Pharma, Inc. reported new preclinical data showing its novel direct-acting antivirals have pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes hantavirus, which is essential for replication and transcription.

The Company highlighted in vitro potency data with superior activity, including IC50 values below 50 nM against hantaan virus, a close relative of the Andes hantavirus strain linked to recent outbreaks. Cocrystal also noted that its first pan-viral protease inhibitor, CDI-988, has advanced into a Phase 1b norovirus challenge study in the United States, while it works to develop a pan-viral lead molecule and explore potential collaborations to address viral diseases that currently lack approved treatments or vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
current report
Form 10-Q
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
quarterly report

FAQ

How many Cocrystal Pharma (COCP) SEC filings are available on StockTitan?

StockTitan tracks 57 SEC filings for Cocrystal Pharma (COCP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cocrystal Pharma (COCP)?

The most recent SEC filing for Cocrystal Pharma (COCP) was filed on November 16, 2026.